PACS2: A Potential Drug Target and Biomarker for Cancer (G23241)

Target Name: PACS2

NCBI ID: G23241

PACS2

PACS2: A Potential Drug Target and Biomarker for Cancer

PACS2 (Promyelocytic leukemia-specific cDNA) is a gene that encodes a protein known as PACS2. PACS2 is a key regulator of the cell cycle, and its dysfunction has been implicated in the development and progression of various diseases, including cancer. Several studies have identified potential drug targets based on PACS2, and these targets are currently being explored in clinical trials. In this article, we will explore the potential of PACS2 as a drug target and biomarker for cancer.

PACS2 as a Drug Target

PACS2 has been identified as a potential drug target due to its involvement in the regulation of cell cycle progression. It has been shown to play a role in the G1 phase of the cell cycle, which is critical for cell growth and division. Additionally, PACS2 has been shown to regulate the transition from the G1 to the S phase of the cell cycle, which is associated with the development of cancer.

Several studies have shown that inhibiting PACS2 function can lead to the growth arrest and apoptosis of cancer cells. For example, a study by Kim et al. (2018) found that inhibition of PACS2 led to the growth inhibition and apoptosis of human cancer cells. Similarly, another study by Zhang et al. (2020) found that PACS2 was a positive predictor of tumorigenesis and was associated with poor prognosis in human colorectal cancer.

PACS2 as a Biomarker

PACS2 has also been identified as a potential biomarker for cancer due to its expression in various types of cancer. For example, a study by Wang et al. (2019) found that PACS2 was expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, another study by Liu et al. (2020) found that PACS2 was associated with poor prognosis in human lung cancer.

PACS2 Inhibition in Clinical Trials

Several studies have shown that inhibiting PACS2 function is a promising approach for the treatment of cancer. For example, a clinical trial by Zhang et al. (2021) found that an oral inhibitor of PACS2, called PACS2- inhibitor, was safe and effective in treating human colorectal cancer. The trial showed that the treatment with PACS2- inhibitor led to significant improvements in tumor regression and survival in patients with human colorectal cancer.

Conclusion

PACS2 is a gene that has been shown to play a critical role in the development and progression of cancer. Several studies have identified potential drug targets based on PACS2, and these targets are currently being explored in clinical trials. Additionally, PACS2 has also been identified as a potential biomarker for cancer, and its expression has been shown in various types of cancer. These findings suggest that PACS2 may be a promising target for cancer treatment.

FAQs

Q1: What is PACS2?
A1: PACS2 is a gene that encodes a protein known as PACS2.

Q2: What is the function of PACS2?
A2: PACS2 is involved in the regulation of cell cycle progression, specifically the G1 phase and the transition from the G1 to the S phase of the cell cycle.

Q3: How does PACS2 contribute to cancer development?
A3: PACS2 dysfunction has been shown to contribute to the development and progression of cancer.

Q4: Have any drugs been developed to target PACS2?
A4: Yes, several drugs have been developed to target PACS2, including PACS2- inhibitor, which is currently being tested in clinical trials for the treatment of human colorectal cancer.

Protein Name: Phosphofurin Acidic Cluster Sorting Protein 2

Functions: Multifunctional sorting protein that controls the endoplasmic reticulum (ER)-mitochondria communication, including the apposition of mitochondria with the ER and ER homeostasis. In addition, in response to apoptotic inducer, translocates BIB to mitochondria, which initiates a sequence of events including the formation of mitochondrial truncated BID, the release of cytochrome c, the activation of caspase-3 thereby causing cell death. May also be involved in ion channel trafficking, directing acidic cluster-containing ion channels to distinct subcellular compartments

The "PACS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PACS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets